文献速递耳科与耳神经小儿耳鼻咽喉

(缬)更昔洛韦对先天性巨细胞病毒感染听力影响的一项系统综述

The Effect of (Val)ganciclovir on Hearing in Congenital Cytomegalovirus: A Systematic Review.
PubMed 文献 · Laryngoscope · 2022-01-24

该系统综述检索截至2021年12月15日的PUBMED、EMBASE和WEB OF SCIENCE,纳入18项研究共682例接受(缬)更昔洛韦治疗的患儿。Meta分析显示,对有症状且伴听力损失的患儿,治疗组听力改善更多(Peto OR 7.72,95%CI 3.08-19.34),听力恶化更少(Peto OR 0.23,95%CI 0.10-0.57)。作者认为证据足以支持对有症状cCMV伴听力损失患儿进行治疗,但对孤立性听力损失、迟发性听力损失和无症状cCMV患儿证据仍不足。

要点

  • 有症状cCMV伴听力损失患儿接受(缬)更昔洛韦治疗,听力改善Peto OR 7.72(95%CI 3.08-19.34)。
  • 治疗组听力恶化Peto OR 0.23(95%CI 0.10-0.57),优于未治疗组。
  • 孤立性、迟发性听力损失及无症状cCMV患儿证据仍不足。

核心结论

  • 现有文献证据足以支持对有症状先天性巨细胞病毒感染伴听力损失的儿童使用(缬)更昔洛韦治疗。
  • 对孤立性听力损失、迟发性听力损失和无症状先天性巨细胞病毒感染患儿,(缬)更昔洛韦对听力结局的潜在有益作用证据仍不足。
  • 仍迫切需要未来的前瞻性随机临床试验。
  • 定义和治疗方案的标准化将使未来研究具有一致性。

研究设计与样本

  • 系统综述,遵循系统综述和Meta分析优先报告条目指南。
  • 于2021年12月15日在PUBMED、EMBASE和WEB OF SCIENCE进行检索。
  • 纳入报告先天性巨细胞病毒感染相关听力损失儿童接受(缬)更昔洛韦治疗后耳特异性听力结果的研究。
  • 系统综述共纳入18项研究、682例接受治疗的患者。
  • 采用Peto比值比(OR)和Review Manager 5.3进行Meta分析,比较治疗与未治疗儿童的听力结局。

主要发现

  • Meta分析显示,治疗有症状伴听力损失患儿带来更多听力改善(Peto OR 7.72,95%CI 3.08-19.34)。
  • 治疗有症状伴听力损失患儿带来更少听力恶化(Peto OR 0.23,95%CI 0.10-0.57)。
  • 未治疗组听力改善率和恶化率分别为9.4%和28.2%,治疗组分别为44.5%和6.3%。

临床怎么用

  • 作者认为现有文献证据足以支持对有症状先天性巨细胞病毒感染伴听力损失儿童使用(缬)更昔洛韦治疗。
  • 作者指出对孤立性听力损失、迟发性听力损失和无症状先天性巨细胞病毒感染患儿,(缬)更昔洛韦对听力结局的潜在有益作用证据仍不足。
  • 作者认为仍迫切需要未来的前瞻性随机临床试验。

局限性

  • 对孤立性听力损失、迟发性听力损失和无症状先天性巨细胞病毒感染患儿,(缬)更昔洛韦对听力结局的潜在有益作用证据仍不足。
  • 仍迫切需要未来的前瞻性随机临床试验。
  • 定义和治疗方案的标准化将使未来研究具有一致性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To search for existing evidence of a beneficial effect of (val)ganciclovir on hearing in children with congenital cytomegalovirus (cCMV) infection and to identify future research questions. STUDY DESIGN: Systematic review following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines, searches were performed in PUBMED, EMBASE, and WEB OF SCIENCE on December 15, 2021. METHODS: Studies providing ear-specific hearing results after treating children with cCMV-related hearing loss with (val)ganciclovir were retained. A meta-analysis [Peto odds ratio (OR), Review Manager 5.3] was performed to compare hearing outcome between treated and untreated children. The National Institutes of Health tool was used for quality assessment and heterogeneity was assessed with I2 statistics. RESULTS: Eighteen studies with a total of 682 treated patients were included for the systematic review. Our meta-analysis showed that treating symptomatic children with hearing loss resulted in more hearing improvement [Peto OR 7.72, 95% confidence interval (CI) 3.08-19.34] and less hearing deterioration (Peto OR 0.23, 95% CI 0.10-0.57). Relative to an improvement and deterioration rate of 9.4% and 28.2% in an untreated group, the rate of the treated group was 44.5% and 6.3%, respectively. CONCLUSIONS: There is sufficient evidence in literature to support treatment with (val)ganciclovir of children with symptomatic cCMV and hearing loss. However, still today, there is insufficient evidence of the potential beneficial role of (val)ganciclovir on hearing outcome of children with isolated hearing loss, late-onset hearing loss, and asymptomatic cCMV. The urgent need for future prospective, randomized clinical trials still exists. A standardization of definitions and treatment protocols would create uniformity in future studies. Laryngoscope, 132:2241-2250, 2022.

来源:Laryngoscope,查看原文。版权归原作者所有。

引用

  1. De Cuyper E, Acke F, Keymeulen A, et al. The Effect of (Val)ganciclovir on Hearing in Congenital Cytomegalovirus: A Systematic Review. Laryngoscope. 2022. PMID: 35072277. doi:10.1002/lary.30027

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。